BioSpace News Archive

Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus vaccine candidate.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2024 financial results after market close on Tuesday, May 7, 2024.

NeuroBo Pharmaceuticals, Inc. today announced the acceptance of poster presentations for its promising cardiometabolic assets, DA-1241 and DA-1726, at the EASL Congress 2024 and the American Diabetes Association.

Ansa Biotechnologies, Inc. today announced its speaker lineup for presentations at the upcoming Global Synthetic Biology (SynBioBeta) Conference in San Jose, Calif., from May 6-9, 2024.

Akili, Inc. including an amendment to its strategic distribution agreement with Shionogi & Co., Ltd. (“Shionogi”), a leading global pharmaceutical company.

Lineage Cell Therapeutics, Inc. today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM).

Nanjing Leads Biolabs Co., Ltd. announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to conduct the single-arm pivotal study for registration and market authorization from the Center for Drug Evaluation of the National Medical Products Administration.

Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the patent estate related to AVIM Therapy has reached 110 patents worldwide.

Inflammatory bowel disease is a common chronic gastrointestinal disorder and current treatment strategies can cause adverse effects.

Silence Therapeutics plc today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference.